← Leaderboards
Jean-Frederic Colombel
Icahn School Of Medicine At Mount Sinai
$960,589
Attributed
$2,881,766
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $594.9K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,881,766 · 1
By mechanism
U01$2,881,766 · 1
Top collaborators
- Jeremiah James Faith5 shared
- Sacha Gnjatic5 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Miriam Merad$28,468,631
- Randy A. Albrecht$3,614,675
- Poulikos I Poulikakos$5,543,909
- Jenny J. Lin$6,197,650
- Chung Yin Kong$10,200,842
Others in their field
Other Emerging Leaders on “Ctla4 Gene”
- Sana D Karam · University Of Colorado Denver$3,185,899
- Zachary Scott Morris · University Of Wisconsin-Madison$3,060,418
- Nicholas Arpaia · Columbia Univ New York Morningside$3,029,358
- Christiane Querfeld · Beckman Research Institute/City Of Hope$2,825,258
- Evan Newell · Fred Hutchinson Cancer Research Center$2,763,230
- William Karl Decker · Baylor College Of Medicine$2,625,276
Research focus
Ctla4 GeneAnti-Ctla416s Ribosomal Rna SequencingCtla4 BlockadeAutoantibodiesBacterial CommunityAntimicrobialAntibodiesBiological MarkersAnti-Pd-1BiopsyBloodCancer ImmunotherapyCancer PatientCellsClinicClinical DevelopmentClinical Trials DesignColitisColorectalCombination ImmunotherapyCombined Modality TherapyCrohn&AposCytokine
Grant awards (5)
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$554,399
U01 · FY2024 · DK
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$577,498
U01 · FY2023 · DK
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$577,498
U01 · FY2022 · DK
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$577,498
U01 · FY2021 · DK
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$594,873
U01 · FY2020 · DK